Clinical research
Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma.
SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. The company plans to use the money to advance its pipeline.
Biogen is going all-in on a stroke drug it has been developing for the past three years in collaboration with Japan-based TMS Co.
Clearance of the IND allows Samus to proceed with a Phase Ib trial to assess the safety, tolerability and pharmacokinetics of PU-AD in a small group of patients with recurrent malignant glioma.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 11, 2021.
Shanghai-based Alebund Pharmaceuticals has raised $60 million in a new Series B financing round that will be harnessed to further drive the company’s focus on renal disease.
jCyte Inc. presented the results from its Phase IIb study and a detailed analysis of the study’s optical coherence tomography (OCT) data last week at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M are working together on a potential vaccine that might protect individuals against multiple variants of SARS-CoV-2.
A final analysis of AstraZeneca’s Phase III POSEIDON trial shows IMFINZI (durvalumab), offered improvements in overall survival (OS) when added to tremelimumab and chemotherapy versus chemotherapy alone in patients with Stage IV (metastatic) non-small cell lung cancer.
It was a busy week for clinical trial news. Here’s a look.
PRESS RELEASES